These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 25330222)

  • 41. Allogeneic hematopoietic stem cell transplantation in adults with myelodysplastic syndrome: Experience of the Argentinean Group of Bone Marrow Transplantation (GATMO).
    Basquiera AL; Rivas MM; Remaggi G; Klein G; Milovic V; Foncuberta MC; Saba S; Milone JH; Arbelbide J; Jaimovich G; Rolón JM; Kusminsky G; García JJ; Prates MV
    Hematology; 2016 Apr; 21(3):162-9. PubMed ID: 26147089
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Emerging therapeutic strategies for myelodysplastic syndrome.
    Barrett J; Battiwalla M
    Curr Hematol Rep; 2003 May; 2(3):193-201. PubMed ID: 12901340
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Hematopoietic stem cell transplantation for myelodysplastic syndrome.
    Parmar S; de Lima M
    Biol Blood Marrow Transplant; 2010 Jan; 16(1 Suppl):S37-44. PubMed ID: 19857589
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Pretreatment CD34
    Jentzsch M; Geus U; Grimm J; Vucinic V; Pönisch W; Franke GN; Behre G; Niederwieser D; Schwind S
    Biol Blood Marrow Transplant; 2019 Aug; 25(8):1560-1566. PubMed ID: 30928626
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Outcome after relapse of myelodysplastic syndrome and secondary acute myeloid leukemia following allogeneic stem cell transplantation: a retrospective registry analysis on 698 patients by the Chronic Malignancies Working Party of the European Society of Blood and Marrow Transplantation.
    Schmid C; de Wreede LC; van Biezen A; Finke J; Ehninger G; Ganser A; Volin L; Niederwieser D; Beelen D; Alessandrino P; Kanz L; Schleuning M; Passweg J; Veelken H; Maertens J; Cornelissen JJ; Blaise D; Gramatzki M; Milpied N; Yakoub-Agha I; Mufti G; Rovira M; Arnold R; de Witte T; Robin M; Kröger N
    Haematologica; 2018 Feb; 103(2):237-245. PubMed ID: 29101205
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Monocyte recovery at day 100 is associated with improved survival in multiple myeloma patients who undergo allogeneic hematopoietic cell transplantation.
    Dhakal B; Brazauskas R; Lara CA; Hari P; Pasquini M; D'Souza A
    Bone Marrow Transplant; 2016 Feb; 51(2):297-9. PubMed ID: 26457907
    [No Abstract]   [Full Text] [Related]  

  • 47. Allogeneic hematopoietic cell transplantation for myelodysplastic syndromes: lingering uncertainties and emerging possibilities.
    Mukherjee S; Boccaccio D; Sekeres MA; Copelan E
    Biol Blood Marrow Transplant; 2015 Mar; 21(3):412-20. PubMed ID: 25079875
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Total body irradiation dose escalation decreases risk of progression and graft rejection after hematopoietic cell transplantation for myelodysplastic syndromes or myeloproliferative neoplasms.
    Monaco F; Scott BL; Chauncey TR; Petersen FB; Storer BE; Baron F; Flowers ME; Deeg HJ; Maloney DG; Storb R; Sandmaier BM
    Haematologica; 2019 Jun; 104(6):1221-1229. PubMed ID: 30630975
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Development of acute myeloid leukemia in a myelodysplastic syndrome patient after allogeneic hematopoietic stem cell transplantation for 12 years: a case report and literature review].
    Li Z; Zhang Y; Zhou J; Fang B; Lin Q; Song Y
    Zhonghua Xue Ye Xue Za Zhi; 2014 Jan; 35(1):63-5. PubMed ID: 24602738
    [No Abstract]   [Full Text] [Related]  

  • 50. Comparative effectiveness of busulfan/cyclophosphamide versus busulfan/fludarabine myeloablative conditioning for allogeneic hematopoietic cell transplantation in acute myeloid leukemia and myelodysplastic syndrome.
    Patel SS; Rybicki L; Pohlman B; Bolwell B; Gerds AT; Hamilton BK; Hanna R; Kalaycio M; Majhail NS; Sobecks R
    Hematol Oncol Stem Cell Ther; 2020 Sep; 13(3):160-165. PubMed ID: 31628924
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Relapse after Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndromes: Analysis of Late Relapse Using Comparative Karyotype and Chromosome Genome Array Testing.
    Yeung CCS; Gerds AT; Fang M; Scott BL; Flowers MED; Gooley T; Deeg HJ
    Biol Blood Marrow Transplant; 2015 Sep; 21(9):1565-1575. PubMed ID: 25953732
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Allogeneic haematopoietic cell transplantation with reduced-intensity conditioning for elderly patients with advanced myelodysplastic syndromes: a nationwide study.
    Aoki K; Ishikawa T; Ishiyama K; Aoki J; Itonaga H; Fukuda T; Kakihana K; Uchida N; Ueda Y; Eto T; Mori T; Kondo T; Iwato K; Morishima Y; Tanaka J; Atsuta Y; Miyazaki Y;
    Br J Haematol; 2015 Feb; 168(3):463-6. PubMed ID: 25228239
    [No Abstract]   [Full Text] [Related]  

  • 53. Haploidentical bone marrow transplantation in patients with advanced myelodysplastic syndrome.
    Varaldo R; Raiola AM; Di Grazia C; Aquino S; Beltrami G; Bregante S; Cruciani F; Dominietto A; Ghiso A; Giannoni L; Gualandi F; Ibatici A; Lamparelli T; Marani C; Van Lint MT; Santini V; Bacigalupo A; Angelucci E
    Am J Hematol; 2017 Jun; 92(6):E117-E119. PubMed ID: 28316085
    [No Abstract]   [Full Text] [Related]  

  • 54. Diagnosing therapy-related acute myeloid leukemia with 8% blasts in bone marrow with concomitant plasma cell myeloma.
    Thakral B; Muzzafar T
    Blood; 2017 Jul; 130(2):231. PubMed ID: 28705862
    [No Abstract]   [Full Text] [Related]  

  • 55. Increased opportunity for prolonged survival after allogeneic hematopoietic stem cell transplantation in patients aged 60-69 years with myelodysplastic syndrome.
    Itonaga H; Ishiyama K; Aoki K; Aoki J; Ishikawa T; Uchida N; Ohashi K; Ueda Y; Fukuda T; Sakura T; Ohno Y; Iwato K; Okumura H; Kondo T; Ichinohe T; Takanashi M; Atsuta Y; Miyazaki Y
    Ann Hematol; 2019 Jun; 98(6):1367-1381. PubMed ID: 30854574
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Red cell and platelet transfusion burden following myeloablative allogeneic haemopoietic stem cell transplantation.
    Le Viellez A; P'Ng S; Buffery S; Wright M; Cooney J; Cannell P; Purtill D
    Intern Med J; 2015 Dec; 45(12):1286-92. PubMed ID: 26348642
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Myelodysplastic syndrome.
    Nakao S; Deeg HJ; Ishikawa T; Marsh J; List A; Tomonaga M
    Int J Hematol; 2005 Dec; 82(5):412-6. PubMed ID: 16533744
    [No Abstract]   [Full Text] [Related]  

  • 58. [Progress of research on allogeneic hematopoietic stem cell transplantation with reduced-intensity conditioning regimen for treatment of myelodysplastic syndrome - review].
    Zhang Z; Li X
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2008 Aug; 16(4):969-74. PubMed ID: 18718102
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The current and future role of stem cells in myelodysplastic syndrome therapies.
    Kobbe G; Schroeder T; Haas R; Germing U
    Expert Rev Hematol; 2018 May; 11(5):411-422. PubMed ID: 29547016
    [TBL] [Abstract][Full Text] [Related]  

  • 60. CD34+ chimerism analysis for minimal residual disease monitoring after allogeneic hematopoietic cell transplantation.
    Unnikrishnan A; Meacham AM; Goldstein SS; Ta M; Leather HL; Cogle CR; Castillo P; Wingard JR; Norkin M
    Leuk Res; 2018 Nov; 74():110-112. PubMed ID: 30401521
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.